Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ImmunityBio, Inc. securities between January 19, 2026, and March 24, 2026, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Patrick Soon-Shiong, a defendant, materially overstated the capabilities of Anktiva, leading to false and misleading statements about ImmunityBio's business and operations [5]. - Investors who purchased ImmunityBio securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 26, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has been ranked highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by May 26, 2026 [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether ImmunityBio and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased or acquired ImmunityBio securities during the Class Period are encouraged to contact Pomerantz LLP to potentially become Lead Plaintiffs [2]. Group 2: FDA Warning - On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) to ImmunityBio became public, stating that the company continued to promote its bladder-cancer drug, Anktiva, in a misleading manner despite previous warnings [4]. - The FDA's letter highlighted concerns regarding the accuracy of the company's promotions, including television advertisements and a podcast appearance [4]. Group 3: Stock Price Impact - Following the news of the FDA warning, ImmunityBio's stock price fell by $1.99 per share, representing a decline of 21.12%, closing at $7.41 per share on March 24, 2026 [5].

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment but has not demonstrated long-term efficacy as stated by the company [4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion of Anktiva being a cancer vaccine is false, and the Executive Chairman overstated its capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is representing the investors in this class action and has a strong track record in securities fraud litigation, recovering over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) for securities fraud, encouraging shareholders to inquire about their rights and potential recovery of losses [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, with a deadline for filing a lead plaintiff motion set for May 26, 2026 [1]. - The lawsuit alleges that the company's Executive Chairman, Patrick Soon-Shiong, made false claims about the lead biologic product, Anktiva, including that it "can cure and even prevent all cancer," which the FDA deemed misleading [3][4]. Group 2: Impact on Shareholders - Following the FDA's warning on March 24, 2026, ImmunityBio's stock price dropped by $1.98, or 21.12%, closing at $7.42 per share, resulting in significant losses for investors [3]. - The complaint asserts that the defendants failed to disclose material adverse facts about the company's business and operations, leading to misleading statements regarding its prospects [4].

Group 1 - ImmunityBio Inc. (NASDAQ:IBRX) is recognized as a high growth healthcare stock, particularly in the immunotherapy sector, focusing on cancer and infectious diseases [3] - The FDA issued a warning letter regarding ImmunityBio's promotional communications for its product Anktiva, stating that the TV ad and podcast were deemed false or misleading [1][2] - The company has been directed by the FDA to cease the misleading advertisements and respond to the concerns within 15 working days [2] Group 2 - ImmunityBio's immunotherapy platform aims to activate both the adaptive and innate immune systems to establish long-term immunological memory [3] - Despite the potential of IBRX as an investment, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ImmunityBio, Inc. due to allegations of false and misleading statements made by the company and its executives regarding its product Anktiva, which may have led to investor losses [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in ImmunityBio between January 19, 2026, and March 24, 2026, to contact them to discuss their legal options [1]. - A federal securities class action has been filed against ImmunityBio, with a deadline of May 26, 2026, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Patrick Soon-Shiong, a defendant, materially overstated Anktiva's capabilities, leading to misleading statements about the company's business and operations [4]. Group 2: Stock Performance - Following the announcement of updated Phase 2 clinical results for a treatment regimen in glioblastoma patients on January 23, 2026, ImmunityBio's stock price fell by $0.89 per share, or 12.13%, closing at $6.45 per share [5]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ImmunityBio, Inc. securities for the period between January 19, 2026, and March 24, 2026, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Patrick Soon-Shiong, a defendant, materially overstated the capabilities of Anktiva, leading to false and misleading statements about ImmunityBio's business and operations [5]. - Investors who purchased ImmunityBio securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 26, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - ImmunityBio, Inc. is facing a securities fraud class action lawsuit due to a significant stock decline of 21% following an FDA warning regarding misleading advertising related to its cancer treatment, Anktiva [1][4]. Company Overview - ImmunityBio, Inc. (NasdaqGS: IBRX) is under scrutiny for failing to disclose material information during the class period from January 19, 2026, to March 24, 2026 [3][5]. - The company's stock price fell by $1.98, closing at $7.42 per share on March 24, 2026, after the FDA's warning letter was made public [4]. Legal Proceedings - Investors who suffered substantial losses have until May 26, 2026, to file lead plaintiff applications in the ongoing class action lawsuit against ImmunityBio [1][5]. - The lawsuit is currently pending in the United States District Court for the Central District of California, under the case name Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261 [5]. FDA Warning Details - The FDA issued a warning letter on March 13, 2026, indicating that ImmunityBio's promotional materials misrepresented Anktiva, suggesting it could cure and prevent all cancers, which violates the Federal Food, Drug, and Cosmetic Act [4].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly making false and misleading statements regarding its product Anktiva, leading to investor losses during the specified class period from January 19, 2026, to March 24, 2026 [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Central District of California on behalf of all individuals and entities who purchased ImmunityBio securities during the class period [2]. - Investors have until May 26, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The lawsuit alleges that Patrick Soon-Shiong, a defendant, materially overstated the capabilities of Anktiva, resulting in false and misleading statements about ImmunityBio's business and prospects [3]. - The claims suggest that when the true information became public, investors suffered damages due to the misleading nature of the defendants' statements [3]. Group 3: Next Steps for Investors - Investors who purchased ImmunityBio shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The law firm offers assistance without any cost or obligation to the investors [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases [5]. - The firm operates nationwide and has offices in New York, South Carolina, and California [5].

Core Viewpoint - ImmunityBio, Inc. is facing a securities class action lawsuit following a warning from the FDA regarding misleading claims about its cancer treatment product, Anktiva, which has resulted in a significant drop in the company's market capitalization by nearly $2 billion [1][7]. Group 1: Lawsuit and FDA Warning - The class action lawsuit seeks to represent investors who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026 [1]. - The FDA issued a warning letter to ImmunityBio concerning claims made by its executive chairman, Dr. Patrick Soon-Shiong, about Anktiva's efficacy, which the FDA deemed misleading [2][7]. - Following the FDA's warning, ImmunityBio's share price fell over 21% on March 24, 2026, leading to a loss of nearly $2 billion in market capitalization [2][7]. Group 2: Company Background and Product Information - ImmunityBio is a biotechnology company focused on developing immunotherapies aimed at activating the immune system to combat cancer and infectious diseases [4]. - Anktiva is an FDA-approved immunotherapy used in conjunction with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) [5]. - The lawsuit centers on the legitimacy of ImmunityBio's claims regarding Anktiva's effectiveness in treating other types of cancer beyond its approved indication [5][6]. Group 3: Investigation and Implications - Hagens Berman, a national shareholders rights firm, is investigating claims that ImmunityBio violated federal securities laws by misleading investors about Anktiva's efficacy [3][8]. - The FDA's warning highlighted that promotional materials created a misleading impression that Anktiva could cure and prevent all cancers, which has not been substantiated by data [7]. - The firm is encouraging investors who suffered losses to come forward and is also seeking witnesses to assist in the investigation [3][8].